Critical Comparison: Blue Water Acquisition Corp. III (NASDAQ:BLUW) and Protalix BioTherapeutics (NYSE:PLX)

Protalix BioTherapeutics (NYSE:PLX) and Blue Water Acquisition Corp. III (NASDAQ:BLUW) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Analyst Recommendations

This is a breakdown of current ratings for Protalix BioTherapeutics and Blue Water Acquisition Corp. III, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0	0	1	0	3.00
Blue Water Acquisition Corp. III	1	0	0	0	1.00

Protalix BioTherapeutics presently has a consensus target price of $12.00, indicating a potential upside of 404.20%. Given Protalix BioTherapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Protalix BioTherapeutics is more favorable than Blue Water Acquisition Corp. III.

Valuation & Earnings

This table compares Protalix BioTherapeutics and Blue Water Acquisition Corp. III”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$76.38 million	2.51	$8.31 million	$0.18	13.22
Blue Water Acquisition Corp. III	N/A	N/A	N/A	N/A	N/A

Protalix BioTherapeutics has higher revenue and earnings than Blue Water Acquisition Corp. III.

Insider & Institutional Ownership

16.5% of Protalix BioTherapeutics shares are held by institutional investors. 6.7% of Protalix BioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Protalix BioTherapeutics and Blue Water Acquisition Corp. III’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
Blue Water Acquisition Corp. III	N/A	N/A	N/A

Summary

Protalix BioTherapeutics beats Blue Water Acquisition Corp. III on 6 of the 9 factors compared between the two stocks.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

About Blue Water Acquisition Corp. III

Blue Water Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Greenwich, Connecticut.